E Fund Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-40,461
| Closed | -$585K | – | 504 |
|
|
2026
Q1 | $585K | Buy |
+40,461
| New | +$580K | 0.02% | 256 |
|
|
2025
Q2 | $265K | Buy |
46,326
+22,610
| +95% | +$146K | 0.01% | 326 |
|
|
2025
Q1 | $194K | Buy |
23,716
+21
| +0.1% | +$194 | 0.01% | 365 |
|
|
2024
Q4 | $223K | Sell |
23,695
-2,472
| -9% | -$25.7K | 0.01% | 349 |
|
|
2024
Q3 | $279K | Sell |
26,167
-1,567
| -6% | -$17.1K | 0.01% | 271 |
|
|
2024
Q2 | $275K | Sell |
27,734
-7,498
| -21% | -$77K | 0.02% | 244 |
|
|
2024
Q1 | $415K | Sell |
35,232
-7,316
| -17% | -$93.6K | 0.03% | 206 |
|
|
2023
Q4 | $604K | Buy |
42,548
+6,171
| +17% | +$70.1K | 0.04% | 124 |
|
|
2023
Q3 | $442K | Buy |
36,377
+1,510
| +4% | +$19.5K | 0.03% | 146 |
|
|
2023
Q2 | $438K | Buy |
34,867
+1,109
| +3% | +$13.2K | 0.03% | 141 |
|
|
2023
Q1 | $374K | Sell |
33,758
-2,403
| -7% | -$29.6K | 0.03% | 189 |
|
|
2022
Q4 | $442K | Sell |
36,161
-5,551
| -13% | -$62.5K | 0.04% | 158 |
|
|
2022
Q3 | $435K | Sell |
41,712
-10,727
| -20% | -$120K | 0.04% | 162 |
|
|
2022
Q2 | $563K | Buy |
52,439
+23,564
| +82% | +$194K | 0.05% | 125 |
|
|
2022
Q1 | $273K | Buy |
28,875
+12,006
| +71% | +$113K | 0.01% | 228 |
|
|
2021
Q4 | $195K | Buy |
16,869
+1,098
| +7% | +$12.2K | 0.01% | 267 |
|
|
2021
Q3 | $151K | Buy |
+15,771
| New | +$161K | 0.01% | 250 |
|
|
2021
Q1 | $127K | Buy |
+12,862
| New | +$199K | 0.01% | 230 |
|
Other funds holding FOLD
E Fund Management's FOLD Position: Q2 2026 in Review
E Fund Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 40,461 shares — an estimated $585K sold.
E Fund Management first reported a position in FOLD in Q1 2021 and held it in 18 quarters. The position peaked at $604K in Q4 2023. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- E Fund Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- E Fund Management sold 40,461 Amicus Therapeutics shares in Q2 2026, an estimated $585K.
- E Fund Management first reported a position in Amicus Therapeutics in Q1 2021 and held it in 18 quarters.
- E Fund Management's Amicus Therapeutics position peaked at $604K in Q4 2023.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.